Ironwood Pharmaceuticals, Inc. - Class A (IRWD) Dividend History

Company News

• Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug

  Ironwood Pharmaceuticals' stock plunged after the FDA requested a confirmatory Phase 3 trial for its gastrointestinal drug apraglutide, despite strong data from the initial trial.

  Benzinga

  Featured Companies: GS
• Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

  Beam Therapeutics, a biotechnology company developing precision genetic medicines, has appointed Sravan K. Emany as its new Chief Financial Officer. Emany brings extensive experience in the life sciences industry and will help guide Beam's growth and capital allocation strategy.

  GlobeNewswire Inc.

  Featured Companies: ASRT BEAM IART
• New Strong Sell Stocks for July 5th - Zacks Investment Research

  Three stocks were added to the Zacks Rank #5 (Strong Sell) list today: Arcos Dorados Holdings Inc., Ironwood Pharmaceuticals, Inc., and Avnet, Inc. The Zacks Consensus Estimate for their current year earnings has been revised downward over the last 60 days.

  Zacks Investment Research

  Featured Companies: ARCO AVT
• Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates

  Ironwood (IRWD) incurs loss in the first quarter of 2024. Revenues decline year over year and miss estimates. The company lowers revenue guidance for 2024. Stock falls.

  Zacks Investment Research

  Featured Companies: ABBV ENTX
• Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q1 Earnings Expected to Decline

  Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  Zacks Investment Research